bioAffinity Technologies, Inc.
BIAF
$-0.05
Change (1 day)
$3.62
Year High
$1.15
Year Low
Categories
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
P/E ratio for bioAffinity Technologies, Inc. (BIAF)
P/E ratio as of 2023: -1.62
According to bioAffinity Technologies, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.62. At the end of 2022 the company had a P/E ratio of -0.88.
P/E ratio history for bioAffinity Technologies, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.62 |
| 2022 | -0.88 |
| 2021 | -9.68 |
| 2020 | -8.42 |
| 2019 | -18.51 |